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II and III from 0.09 to 0.32 to 0.54 procedures per patient-yearVascular access blood flow monitoring reduces access morbid-
at risk for phases I, II, and III, respectively (P 0.01 for phaseity and costs.
III vs. phase I). When the total cost of treatment for thrombosis-Background. Vascular access morbidity results in subopti-
related events for grafts was estimated, it was found that duringmal patient outcomes and costs more than $8000 per patient-
phase III, the adjusted yearly billed amount was reduced byyear at risk, representing approximately 15% of total Medicare
49% versus phase I and 54% versus phase II to $158,550.expenditures for ESRD patients annually. In recent years, the
Similar trends in reduced thrombosis-related morbid eventsrate of access thrombosis has improved following the advent
and cost were observed for AVFs.of vascular access blood flow monitoring (VABFM) programs
Conclusions. VABFM for early detection of vascular accessto identify and treat stenosis prior to thrombosis. To define fur-
malfunction coupled with preventive intervention reducesther both the clinical and financial impact of such programs,
thrombosis rates in both polytetrafluoroethylene (PTFE) graftswe used the ultrasound dilution method to study the effects of
and native AVFs. While there was a significant increase inVABFM on thrombosis-related morbid events and associated
the number of angioplasties done during the flow monitoringcosts, compared with both dynamic venous pressure monitoring
phase, the comprehensive cost is markedly reduced due to the(DVPM) and no monitoring (NM) in arteriovenous fistulas
decreased number of hospitalizations, catheters placed, missed(AVF) and grafts.
Methods. A total of 132 chronic hemodialysis patients were treatments, and surgical interventions. Vascular access blood
followed prospectively for three consecutive study phases (I, flow monitoring along with preventive interventions should be
11 months of NM; II, 12 months of DVPM; III, 10 months of the standard of care in chronic hemodialysis patients.
VABFM). All vascular access-related information (thrombosis
rate, hospitalization, angiogram, angioplasty, access surgery,
thrombectomy, catheter placement, missed treatments) was
The rapid growth of end-stage renal disease (ESRD)collected during the three study periods.
programs in the United States has been accompanied byResults. During the three study phases, graft thrombosis rate
was reduced from 0.71 (phase I), to 0.67 (phase II), to 0.16 a notable increase in hemodialysis vascular access-related
(phase III) events per patient-year at risk (P  0.001 phase morbidity. A recent report from the United States Renal
III vs. phases I and II). Similarly, hospital days, missed treat-
Data System (USRDS) estimated that the average costments, and catheter use related to thrombotic events were
of access morbidity is $7871 per patient per year at risk andsignificantly reduced during phase III compared to phases I
and II. Hospital days related to vascular access morbidity and that the annual global cost to Medicare represents 14 to
adjusted for patient-year at risk were 1.8, 1.6, and 0.4 and 17% of total spending for dialysis patients per year at
missed dialysis treatments were 0.98, 0.86, and 0.26 treatments risk [1]. Recent data also suggest that the cost associated
per patient-year at risk for phases I, II, and III, respectively
with vascular access care may be accelerating [2].(P  0.001 for phase III vs. phases I and II). Catheter use was
Given the magnitude of the problem, significant effortsalso significantly reduced during phases II and III, from 0.29
(phase I) to 0.17 and further to 0.07 catheters per patient- have focused on improving understanding of the patho-
year at risk, respectively (P  0.05 for phase III vs. phase I). physiology and appropriate treatment for vascular access
Percutaneous angioplasty procedures increased during phases morbidity. One of the important achievements in this
field included understanding the need to monitor access
function prospectively in order to detect incipient accessKey words: chronic hemodialysis, thrombosis, graft, fistula, angioplasty,
catheter placement. malfunction [3]. Schwab et al initially proposed dynamic
venous pressure monitoring (DVPM) for the purpose ofReceived for publication October 5, 2000
predicting stenosis in 1989 [4]. Subsequent to the Schwaband in revised form March 13, 2001
Accepted for publication March 30, 2001 studies, Besarab et al utilized static venous pressure mon-
itoring (SVPM) to predict stenosis [5]. The predictive 2001 by the International Society of Nephrology
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capability for access stenosis was greatly advanced with Study design
the development of the ultrasound dilution technique of This study was analysis of data from three phases of
vascular access blood flow (VABF) measurement during access thrombosis monitoring and treatment. The dates
the hemodialysis treatment [6]. Recent studies by our of the study periods were January 1, 1996, to Novem-
laboratory and others have shown that vascular access ber 30, 1996 (phase I), December 1, 1996, to November
flow measurement was a significant and better predictor 30, 1997 (phase II), and December 1, 1997 to Septem-
for stenosis as well as thrombosis compared with other ber 30, 1998 (phase III). Phase I consisted of 11 months
techniques [7–11]. of hemodialysis treatment without access monitoring [no
While prospective monitoring of the vascular accesses monitoring (NM)]. Phase II was a 12-month period of
predicts probable stenosis with a high degree of sensitiv- dynamic venous pressure monitoring, and phase III was
ity and specificity, an important issue that has not been a 10-month period of vascular access blood flow monitor-
clarified is the cost-effectiveness of prospective vascular ing. During phase II, dynamic venous pressure monitor-
access blood flow monitoring combined with a treatment ing was carried out according to the Schwab method of
algorithm for the resolution of the stenosis. The present VP measurement at QB of 200 mL/min during the first
study has been carried out to compare thrombosis rates, five minutes of dialysis each treatment as modified by
hospitalizations, and related costs over three periods of National Kidney Foundation, Dialysis Outcomes Quality
vascular access management. Our hypothesis was that Initiative, Clinical Practice Guidelines for Vascular Ac-
VABFM using the ultrasound dilution method results cess [4]. Patients with VP measurements that were above
in a decrease in thrombosis rate, access-related morbid- the baseline for three consecutive treatments were re-
ity, and associated costs when compared with either no ferred for fistulogram, followed by treatment with angio-
monitoring or with a program of DVPM. plasty or surgery, based on the judgment of the radiolo-
gist. Prior to phase II, all staff was prospectively trained
in DVPM.
METHODS
Phase III of VABFM was carried out according to the
The study was conducted at an outpatient dialysis facil- algorithm depicted in Figure 1. The access flow rate of all
ity. Institutional approval was obtained for the study patients was measured at the start of phase III, monthly
procedures from relevant administrative offices where thereafter, and within one week following any access
the study was conducted. Data were obtained through intervention. All measurements were done in duplicate,
review of existing patient records. and any measurement that would trigger access inter-
A total of 132 chronic hemodialysis patients were en- vention was repeated, before being referred for interven-
rolled throughout the three phases of the study, all from tion. Based on flow measurement results, a fistulogram
the same dialysis facility. Inclusion criteria for the study was done within one week for grafts if (1) flow rate was
were all chronic hemodialysis patients with a permanent 600 mL/min, (2) flow rate reduced by 25% compared
vascular access [native arteriovenous (AV) fistula or syn- with previous month measurement, or (3) flow rate was
thetic graft] treated at the dialysis facility during the study 25% below baseline. For native AV fistulas, fistulogram
period. Patients with a catheter as the primary and only was done if (1) flow was reduced by 25% compared with
vascular access were excluded from the study population. previous month measurement or (2) flow was 25% be-
During the course of the study period, patients were cen- low baseline. Based on the judgment of the radiologist,
sored from the follow-up at the time of the dropout event. patients with vascular lesions were treated by either per-
These were (1) percutaneous catheter placed as the pri- cutaneous angioplasty (PTA) or surgery within one week
mary and only access, (2) transfer out of the facility, (3) from the fistulogram. Of note, the same radiology group
transplantation, and (4) death. consisting of two interventional radiologists was used
All patients were dialyzed three times per week on high- throughout the three phases of the study. After interven-
flux biocompatible membranes (F-80 Fresenius, Concord, tion, a new baseline access flow measurement was done,
CA, USA) on standard bicarbonate dialysate, using a and routine monthly flow measurements were resumed.
volumetric-controlled dialysis delivery system (Fresenius Before implementation of phase III, multidisciplinary
2008H) and 15-gauge fistula needles. Patients were anti- meetings were held to develop a treatment algorithm
coagulated by using systemic heparin, according to a agreeable to all team members (renal nurse, nephrolo-
facility protocol based on 50 U/kg predialysis bolus, and gist, surgeon, radiologist). In addition, three patient-care
1000 U/h continuous intradialytic infusion, which was dis- technicians were trained as experts in performing access
continued during the last 30 minutes of treatment. Hepa- flow measurements and tracking related data, in addi-
rin doses and discontinuation time were adjusted based tion to their usual duties. The facility manager, who
on goals of maintaining clot-free dialyzers and post-treat- facilitated implementation of the treatment algorithm
for each patient, supervised these technicians. Duringment access hemostasis time of less than 20 minutes.
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Fig. 1. Treatment algorithm for vascular ac-
cess blood flow monitoring during phase III.
phase II and phase III, all patients were educated regard- Center financial information data system to calculate the
adjusted yearly charges: $1000 per day for hospitaliza-ing the procedures.
The access management protocol was implemented in tion, $200 per missed treatment, $750 per catheter place-
ment, $6332 per new access/revision procedure, $5000a prospective manner since the beginning of the study,
which included extensive data collection from the begin- per thrombectomy, and $3000 per PTA.
ning of phase I. The data were abstracted from the data-
VABF measurement techniquebase for statistical analysis after the study was completed.
Data abstraction for all patients included data for throm- Hemodialysis VABF was measured by ultrasound ve-
locity dilution technique using the Transonic HD01 he-botic events, PTA and surgical treatments, and all throm-
bosis-related events that included missed dialysis treat- modialysis monitor (Transonic Systems, Inc., Ithaca, NY,
USA). The technique has been validated extensively andments, catheter placements, and hospitalization. The
same study personnel did all the data abstraction, and details can be found elsewhere [6]. In brief, the system
uses two ultrasonic sensors attached to the lines of thethe set of data items abstracted from the database was
consistently the same throughout the study. All of these hemodialysis tubing, one to the arterial and another to
the venous line, approximately two to six inches distantdata items also were tracked routinely in the facility
as part of the facility’s continuous quality improvement from the connection of tubing to dialysis needles. Ini-
tially, blood recirculation is checked in the vascular ac-program and focus on improvement of vascular access
outcomes. For each treatment and thrombosis-related cess while the blood lines are in the normal position.
Then, the blood lines are reversed and ultrafiltration isevent, the associated expense information also was esti-
mated. Specifically, an average charge per procedure was turned off. The blood pump flow is set at 300 mL/min.
A bolus of saline (approximately 10 mL) is released intodetermined according to Vanderbilt University Medical
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Table 1. Characteristics of patient population during study phase I
(no monitoring, NM), phase II (dynamic venous pressure
monitoring, DVPM), and phase III (vascular access
blood flow monitoring, VABFM)
Phase I Phase II Phase III
Parameter NM DVPM VABFM
N patients 104 103 98
N grafts 78 75 62
N fistulae 39 41 43
Age average 55.317.4 56.616.6 56.116.9
Gender % males 51% 54% 59%
Race
Caucasian 70.8% 69.9% 67.6%
African American 29.2% 30.1% 32.4%
Fig. 2. Thrombosis rates of grafts and arteriovenous (AV) fistulas dur-Cause of ESRD
ing study phases I, II, and III. Symbols are: () grafts; ( ) fistulas;HTN 43.7% 44.7% 46.5%
**P  0.001 vs. phases I and II.Diabetes 35.9% 35.9% 34.4%
Lupus 4.9% 2.9% 3.0%
GN 3.9% 4.9% 5.1%
Other 11.6% 11.6% 11.0%
the venous line, diluting the flow of blood in the access
and resulting in changes of sound velocity, which is mea-
sured by the transducers on the lines. This change is
calculated by the Transonic software, giving the VABF
in mL/min.
Statistical analysis
The Generalized Linear Model–Poisson loglinear sta-
tistical procedure was carried out for testing the statisti-
Fig. 3. Access-related event rates for hospitalization (), missed treat-cal associations between the study variables, that is, throm-
ments ( ), and catheter placement () for phases I, II, and III; graftsbosis rate, hospitalization, missed treatments, new ac- only. *P  0.05 vs. phase I; **P  0.001 vs. phases I and II.
cess, and catheter placement rates for the three study
phases. The Poisson loglinear model extends the tradi-
tional linear model to encompass responses such as pro- Thrombosis rates
portions or incidence. For the Poisson loglinear model,
The thrombosis rates during the three phases of thethe probability distribution is the Poisson distribution,
study are shown in Figure 2. Grafts thrombosed at a rateand the maximum likelihood estimators are obtained
of 0.71 events per patient-year at risk during phase I of nothrough iterative reweighted least-squares algorithms.
access monitoring. During phase II of DVPM, the rateThe mixed-effect model was used to adjust the intracor-
decreased marginally to 0.67 events per patient-year atrelation effect for the patients who had more than one
risk. This reduction in thrombosis rate in phase II was notclotting event during the study. For patients with more
statistically significantly different compared to phase I.than one access during the study, the statistical model
During phase III of VABFM, thrombosis rates for graftsfor the crossed-nested design was applied for the data
decreased to 0.16 events per patient-year at risk. Thisanalysis. All tests of significance were two sided, and
reduction in thrombosis rate during phase III was highlydifferences were considered statistically significant when
statistically significantly different compared with eitherP value 0.05. All data were expressed as means  SD.
phase I or phase II (P  0.001 vs. both phases I and II).SAS version 8.0 was used for all analyses.
This reduction represented a 77% decrease in throm-
botic events compared with no monitoring and 76%
RESULTS decrease compared with DVPM; indeed, the thrombo-
Patient characteristics sis rate of PTFE grafts during phase III approached the
thrombosis rate observed in native fistulae. The nativeThe characteristics of the patient population for each
fistula thrombosis rate followed a similar pattern, withstudy phase are found in Table 1. For the 132 patients
0.14, 0.15, and 0.07 events per patient-year at risk forstudied, 104 patients were included in phase I, 103 pa-
phases I, II, and III, respectively. However, the 50% reduc-tients were in phase II, and 98 patients were in phase III.
tion in thrombosis rate observed during phase III wasThere were no significant differences among the study
phases for any of the parameters listed in Table 1. not statistically significant compared with phases I or II.
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Fig. 4. Access-related event rates for hospitalization
(), missed treatments ( ), and catheter placement
() for phases I, II, and III; native fistulas only (*P
0.05 vs. phase I; **P  0.05 vs. phases I and II).
Access-related hospitalization, missed treatments,
and catheter placement
The rate of occurrence of morbid events directly re-
lated to access events and procedures was determined for
hospitalization, missed treatments, and catheter place-
ment. These rates for polytetrafluorolethylene (PTFE)
grafts are shown in Figure 3. Thrombosis-related hospi-
talization was reduced significantly from 1.8 hospital days
per patient-year at risk and 1.6 hospital days per patient-
year at risk in phases I and II, respectively, to 0.4 days
Fig. 5. Angioplasty rates of grafts () and AV fistulas ( ) duringper patient-year at risk in phase III (P 0.001 vs. phases
study phases I, II, and III (*P  0.01 vs. phases II and III).I and II). Similarly, missed treatments were reduced sig-
nificantly from 0.98 events per patient-year at risk in
phase I and 0.86 events per patient-year at risk in phase
II to 0.26 events per patient-year at risk in phase III PTA and surgical procedures
(P  0.001 vs. phases I and II). The need for catheter We further examined the rate of interventional proce-
placement was also reduced from 0.29 events per patient- dures during the three phases of the study. There were
year at risk in phase I and 0.17 events per patient-year substantial increases in angioplasty rates for both PTFE
at risk in phase II to 0.07 events per patient-year at risk grafts and native fistulas during phase II and phase III
(Fig. 5). These rates for PTFE grafts were 0.09, 0.32, andin phase III. The reduction in catheter placement events
0.54 PTA procedures per patient-year at risk for phases I,during phase III was statistically significantly less than
II, and III, respectively (P  0.01 for phase I vs. phasesphase I only (P  0.05 vs. phase I).
II and III). For AVFs, there were 0, 0.09, and 0.21 PTAFigure 4 depicts the same information on hospitaliza-
procedures per patient-year at risk for phases I, II, andtion, missed treatments, and catheter placement for na-
III, respectively (P  NS).tive fistulas. During phase III, hospitalization was sig-
The number of thrombectomy procedures for PTFEnificantly reduced to 0.1 days per patient-year at risk
grafts was not significantly changed from phase I toversus phases I and II (0.72 and 0.47 days per patient-
phase II (0.51 procedures per patient-year at risk vs. 0.36
year at risk, respectively, P  0.05). Missed treatments
procedures per patient-year at risk, P  NS); however,
were reduced from 0.39 missed treatments per patient- during phase III, thrombectomies were reduced signifi-
year at risk during phase I to 0.27 missed treatments per cantly to 0.05 procedures per patient-year at risk (P 
patient-year at risk during phase II and to 0.07 missed 0.05 vs. phases I and II). Of note, there were no throm-
treatments per patient-year at risk during phase III (P bectomies performed for AV fistulas throughout the en-
0.05 for phase III vs. phase I). A reduction in catheter tire study period. The rate of new surgeries (access place-
placement was not statistically significant during the ment and revisions) for PTFE grafts was not significantly
three phases of the study, although there were no cathe- different among the three phases (0.20 procedures per
patient-year at risk for phase I, 0.31 procedures per pa-ters placed during phase III of the study.
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Fig. 6. Survival curve for angioplasty patency
for grafts (solid line) and native AV fistulas
(dashed line). Angioplasty half-life in grafts
was 148 days (N  44) and fistulas was 161
days (N  9).
Table 2. Adjusted yearly charges for thrombosis-related access care for patients with grafts and fistulas
Grafts Fistulae
Phase I Phase II Phase III Phase I Phase II Phase III
Cost item NM DVPM VABFM NM DVPM VABFM
Hospitalization $ 87,275 $ 82,000 $ 20,400 $21,820 $16,000 $ 3,600
Missed treatments 9,600 9,000 2,650 2,400 1,800 480
Catheters 10,650 6,750 2,700 4,090 1,500 0
New access/revisions 62,170 101,312 38,000 41,450 50,656 15,200
Thrombectomy 125,450 95,000 12,000 0 0 0
Angioplasty 13,100 51,000 82,800 0 9,000 21,600
Adjusted yearly cost $308,245 $345,062 $158,550 $69,760 $78,956 $40,880
tient-year at risk for phase II, and 0.14 procedures per grafts was $308,245 for phase I. The billed amount in-
patient-year at risk for phase III). For AV fistulas, there creased during phase II to $345,062, primarily due to an
were again no new accesses placed during phase III, increase in surgical and angioplasty procedures. During
while the new access placement rate was 0.18 procedures phase III, the adjusted yearly billed amount was reduced
per patient-year at risk during phase I and 0.07 proce- by 49% versus phase I and 54% versus phase II to
dures per patient-year at risk during phase II (P  0.001 $158,550. Although total billed amounts for native fistu-
for phase I vs. phase III). lae were only 22 to 26% of the billed amounts for grafts
during each study phase, the trend in cost reduction was
Angioplasty patency similar. For fistulae, the adjusted yearly billed amount
To evaluate the primary patency of the vascular ac- was reduced during phase III by 41% versus phase I and
cesses that underwent angioplasty during the whole study by 48% versus phase II.
period, angioplasty patency was measured from each PTA
to time of repeat PTA, surgery, or clotting event. Fig-
DISCUSSIONure 6 depicts the survival curve for angioplasties done
The results of this study strongly suggest that vascularduring the study. As can be seen, the overall primary pat-
access blood flow monitoring for early detection of vas-ency for those accesses was less than 40% at six months.
cular access malfunction coupled with preventive inter-
Overall cost vention reduces the vascular access thrombosis rate as
well as associated charges when compared with no moni-The cost of access-related morbidities was examined
toring or dynamic venous pressure monitoring in chronicin regard to estimated billed amounts, and is shown in
hemodialysis patients. The overall benefit from this ap-Table 2. When the charges of all morbid events and treat-
proach provides an overall cost cutting of 49% comparedment procedures were combined, the adjusted yearly
billed amount for access-related morbidity for PTFE with no monitoring and 54% compared with dynamic ve-
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nous pressure monitoring. The beneficial effects also are not reach statistical significance, most likely secondary
to the low number of thrombotic events. It is also impor-observed as decreases in the total number catheters in-
serted, thrombectomies, new accesses placed, and missed tant to note that a similar approach for preventive inter-
vention utilizing dynamic venous pressure monitoringtreatments, suggesting additional medical advantage to
the patients. To our knowledge, this is the first study that did not result in any improvement either in PTFE grafts
or AV fistula thrombosis rates. This finding is consistentsystematically evaluates the effects of an early detection
and intervention protocol for vascular accesses on throm- with the recent studies suggesting that DVPM is not
sensitive as an early predictor of vascular accesses at riskbosis as well as hospitalizations and associated costs.
While it is known that vascular access-related morbid- for malfunctioning [8].
The significant reduction in thrombosis rate duringity represents a major portion of the ESRD related costs,
recent data also suggest that this cost associated with vas- phase III for the study translated into significant im-
provements in vascular access-related morbidity. Spe-cular access care may be accelerating. Feldman, Kobrin
and Wasserstein reported that, while access-related mor- cifically, there was a fourfold decrease in vascular access-
related hospital days during this phase of the study. Asbidity accounted for approximately 15% of hospital stays
prior to 1989, more recent evidence suggests that access- expected, the decrease in hospital days greatly reduced
the total hospitalization charges. Yearly adjusted hospi-related morbidity accounts for at least 25% of all hospital
stays and in the first year of dialysis may constitute up talization charges (PTFE grafts and AV fistulas) during
phase III of the study were as low as $24,000 for theto 50% of all patient care costs [2]. These data become
even more relevant to nephrology practice in the face whole study patients. Improvement in hospitalization
cost was not the only financial advantage observed duringof a major interest by Medicare and some Health Mainte-
nance Organizations (HMOs) to capitate medical care the study. Indeed, there was a significant reduction in
the number of missed treatments due to vascular accessto ESRD patients.
In addition to this enormous financial burden, for pa- malfunction during the VABFM phase of the study.
Overall, there was $8870 more revenue available by re-tients, dialysis staff, nephrologists, and surgeons, the fre-
quency and unpredictability with which hemodialysis ducing missed treatments during phase III of the study.
In addition to financial benefits, there were importantvascular access thrombosis develops are immense frus-
trations. Vascular access-related morbidity also contrib- medical advantages of early intervention. Specifically, there
was a significant reduction in number of central venousutes significantly to a reduction in the delivered dose of
dialysis (a major factor in the high relative risk of mortal- catheters placed during the VABFM phase of the study
compared with the other two phases. Given the potentiality of chronic hemodialysis patients) through the use of
temporary catheters or reduced blood flow; importantly, adverse effects of temporary and permanent central ve-
nous catheters, such as risk of infection and delivery ofthis access-related morbidity leads to a significant reduc-
tion in the quality of life of dialysis patients. inadequate dialysis, the medical benefits of early inter-
vention are clear [15]. In addition, during the VABFMThe results of our study clearly indicate that prospec-
tive monitoring of vascular access blood flow coupled phase of the study, there was a remarkable reduction in
the number of new accesses created. It is evident thatwith early intervention significantly reduces thrombosis
rate. This reduction in thrombosis rate was almost 41⁄2- preservation of potential access sites in CHD patients is
critical [3, 16]. Vascular access blood flow monitoringfold in PTFE grafts and twofold in AV fistulas during the
VABFM phase compared with phase I. Earlier studies by seems to provide CHD patients a crucial medical benefit
by preserving future access placement sites. These bene-our laboratory and others have already indicated that
VABFM is the best predictor for future thrombosis [7, fits were most noteworthy for AV fistulas such that there
were no catheters and/or new accesses placed for these8, 11–13]. The novel finding in this study is the fact that
when the vascular access at risk for future malfunction patients during the VABFM phase of the study.
A notable finding of our study was that prospective mon-is detected with VABFM, early intervention by angio-
plasty or surgery significantly reduces the thrombosis itoring of vascular accesses either with DVPM or VABFM
coupled with early intervention significantly increased an-chance in that specific vascular access. Indeed, the throm-
bosis rate for the PTFE grafts during phase III of the gioplasty rates and associated costs. This is an expected
finding, since the treatment algorithms used involved re-study was as low as 0.16 events per patient-year at risk,
which is similar to our native AV fistula thrombosis rate ferral for angiogram during phases II and III. Early de-
tection of vascular accesses at risk with monitoring wouldwithout any monitoring. This rate observed in PTFE
grafts is actually almost half of what has been recom- prompt more frequent arteriograms and this would in
return result in more angioplasties, since there is a ten-mended for native AV fistulas by the NKF-DOQI Clini-
cal Practice Guidelines [14]. The beneficial effect of early dency to perform angioplasty at the same session once
a clinically significant stenosis is determined by arte-intervention also was detectable for AV fistulas. How-
ever, the decrease in the AV fistula thrombosis rate did riograms. This resulted in an increase in utilization of
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PTA procedures during phases II and III compared with strategies were not implemented in a different order at
the beginning of the study; this limitation can only bephase I. However, the increased number of angioplasties
translated to an improvement in thrombosis rates only overcome through the implementation of appropriately
designed clinical trials.during the VABFM phase but not during the DVPM
phase of the study. Furthermore, in spite of increased There have been recent changes in vascular access
care due to financial restrictions by Medicare and privatecost of angioplasties, there was a significant reduction in
surgery-related costs during the VABFM phase of the insurance companies. Specifically, vascular access proce-
dures are more commonly done at outpatient settingstudy, attenuating the increased cost of angioplasties.
Since there was a substantial increase in the number without hospitalization, unless medically required. This
might create an advantage for hospitalization rates dur-of angioplasties during the phases II and III of the study,
we further evaluated primary patency of the vascular ac- ing the final phase of the study. However, there was a
planned multidisciplinary team approach for vascularcesses that underwent angioplasty during the study. The
overall primary patency for those accesses was less than access management at the initiation of our study with
an awareness for the most appropriate care for the pa-40% at six months. This finding suggested that while
early intervention with angioplasty decreases thrombosis tient. The only significant change during the study period
was the availability of additional screening techniques.rates in PTFE grafts and AV fistulas, this improvement
is accompanied by a significant increase in cost and trivial Furthermore, even if the hospitalization is excluded from
analysis, the improvement in other outcome measurespostponement until the next need for intervention. There-
fore, it is essential that treatment algorithms based on (that is, thrombosis rates, missed treatments, catheter
placement, revisions, and thrombectomy) during phaseradiologic findings of the stenotic lesion include alterna-
tive approaches such as surgery for vascular accesses at III is 47% compared with phase II. Therefore, we believe
that the robust findings presented in this study are morerisk. Studies of outcomes would further identify the most
efficacious and cost-effective treatment that provides the than just related to time and selection bias. It should
also be noted that the cost data presented in this studygreatest benefit in access survival.
In spite of the intriguing results presented herein, one are primarily for illustrative purposes and do not reflect
the actual billed and collected amounts. While there mayshould also consider several pitfalls of the study when
interpreting these results. Most importantly, this study be differences between the billing amounts for these
events among institutions, the payment amount by Medi-design is not a randomized design, but utilizes data ob-
tained from prospective cohorts for comparison. Indeed, care is usually fixed for each charge and the costs used
were uniform for all three phases. Accordingly, the costthe only available prospective randomized study failed
to prolong the primary patency of PTFE grafts by pro- associated with morbid events will be directly related to
frequency of those events.phylactic balloon angioplasty [17]. It is possible that the
recognition of the importance of vascular access-related Another potential drawback in the study is that the in-
terventions were decided by the judgment of the radiolo-morbidity and associated costs over the recent years
might provide a potential bias during the final phase of gist, which may introduce subjectivity in the study. How-
ever, the same radiology and surgery groups were utilizedthe study favoring the results for that period. Addition-
ally, there is a possibility that the accesses entering the during the entire study period, which should minimize this
potential bias. The patient population also varied duringfinal phase of the study are “fitter.” This is due to the
possibility that the reservoir of access abnormalities that the three phases of the study, albeit a small percentage.
However, the statistical methodology used in this arti-were manifest in phases I and II were treated, leaving
behind a fitter set of accesses entering phase III. While cle—a generalized linear model—accounted for such dif-
ferences in patient population as well as possible recur-this assumption may be true, there are several indications
that the set of accesses entering phase III were not actu- rent events in the same patient. Finally, an important
issue that has not been clearly delineated by this studyally statistically a “fitter” set. First, there is no statistically
significant change regarding thrombosis rate, hospital is the optimal frequency of sequential screening in order
to detect the access at risk. While in this study measure-days, missed treatments, and catheter use for both grafts
and fistulas from phase I to phase II. Furthermore, the ments of vascular access blood flow were made every
month, other studies suggested that less frequent moni-rate of angioplasty actually increased during phase III
compared with phase II of the study. Therefore, we be- toring, such as every other month or quarterly, might
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